Revvity delivered the quarter its transformation story needed. Adjusted EPS of $1.38 topped the $1.29 consensus and the $1.34 Earnings Whisper number by 3.0%. Revenue of $728.9 million beat expectations by 3.1%. Earnings grew 16.9% year over year, well ahead of 4.3% reported revenue growth. The more important figure was 7% pro forma organic growth, more than double Q2's 3% and above management's own mid-single-digit guide. Management raised full-year guidance for the third straight time. The central tension is that the acceleration was real but not entirely repeatable. Management guided Q4 organic growth back to about 5% and acknowledged that some Q3 upside came from timing.
The quality of the beat is mostly solid. Excluding China IDX, adjusted operating margin expanded to 29.4% from 26.0%, and pro forma adjusted EPS rose to $1.37 from $1.13. GAAP EPS from continuing operations improved to $0.56 from $0.41. However, the gap to adjusted EPS widened because restructuring charges nearly tripled, to $28.4 million from $9.9 million. Investors should treat those charges as a real cost of the margin program. A share count roughly 3% lower than a year ago also helped per-share growth. That benefit is likely to fade, because buybacks nearly stopped this quarter while the company retired $571 million of senior notes. The trade-off left cash at $593 million but cut net leverage to 2.3x from 2.8x in Q1. Free cash flow of $152 million represented 99% conversion, below Q2's 117% but still healthy.
The operating story centers on Life Sciences. Organic growth there swung to +9% from -3% in Q2. Reagents grew high single digits, which management called the strongest in several years. Instruments grew mid single digits, and Signals software grew high teens after falling 20% in Q2. Pharma and biotech growth ex-software improved to high single digits from low single digits. Management said AI-driven demand is spreading beyond high-content screening into high-throughput screening and detection. It also said instrument backlog grew across almost every group, raised its Q4 instruments outlook to high single digits, and is adding high-content screening capacity. Those details point to demand rather than simple restocking.
Diagnostics moved in the opposite direction on growth but the right direction on profitability. Segment organic growth slowed to 5% from 11% in Q2. Reproductive health dropped to low single digits from mid-teens in the first half, pressured by Genomics England comparisons and lighter instrument placements. APAC declined low single digits on China reproductive health and birth-rate headwinds. Even so, Diagnostics margins excluding China IDX topped 30%, up more than 600 basis points, on efficiency actions. The launch of the CE-IVDR type 1 diabetes triplex kit in Europe, plus a broader T1D assay in development with Sanofi, adds a longer-dated growth avenue. The unresolved Genomics England extension and 2027 comparisons remain a risk.
The guidance math frames the setup. Full-year organic growth guidance has risen in steps, from 2-3% initially to about 5% now. EPS guidance moved to $5.40-$5.45 from $5.30-$5.40, and the adjusted operating margin target edged up to 28.8%. Q4's implied deceleration has a clear explanation. Roughly 100 basis points of bulk reagent screening orders were pulled into Q3, and Signals growth is expected to moderate to mid-teens. Incremental reinvestment also absorbed part of the beat. Analysts on the call raised the industry's history of false starts in pharma and biotech recoveries, a legitimate concern after one strong quarter. The November 13 Investor Day, where management is expected to frame 2027, now carries considerable weight.
The market got ahead of the report. Shares rose 32.4% from the open after the August release to $151.60, sit about 35% above the 200-day moving average, and set a 52-week high of $169.06 on October 28. Shares then gave back about 10% before earnings, so investors were already pricing a recovery and trimming exposure into the print. Sentiment improved meaningfully, from -0.20 to -0.04, but remained slightly negative, which signals lingering skepticism rather than euphoria. The Earnings Whispers trend signals are largely positive, with sequential growth neutral, consistent with a quarter that improved sharply but faces a softer near-term comparison.
The bottom line is that Revvity produced a credible inflection: Life Sciences returned to growth, margins kept expanding, and guidance moved higher again. The beat was not flawless, however. Pulled-forward reagent orders, a slowing Diagnostics business, rising restructuring costs, and a fading buyback tailwind all temper the headline. After a 32% run, the stock needs Investor Day to show that Q3 was the start of a durable trend rather than a timing-aided peak.